JP2017516501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516501A5 JP2017516501A5 JP2017515878A JP2017515878A JP2017516501A5 JP 2017516501 A5 JP2017516501 A5 JP 2017516501A5 JP 2017515878 A JP2017515878 A JP 2017515878A JP 2017515878 A JP2017515878 A JP 2017515878A JP 2017516501 A5 JP2017516501 A5 JP 2017516501A5
- Authority
- JP
- Japan
- Prior art keywords
- hybridization
- classifier biomarkers
- biomarkers
- classifier
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims description 94
- 238000009396 hybridization Methods 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 33
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 201000005202 lung cancer Diseases 0.000 claims description 12
- 208000020816 lung neoplasm Diseases 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 9
- 208000009956 adenocarcinoma Diseases 0.000 claims description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 208000002458 carcinoid tumor Diseases 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 208000000649 small cell carcinoma Diseases 0.000 claims description 7
- 230000000955 neuroendocrine Effects 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000013074 reference sample Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 239000003155 DNA primer Substances 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 239000013615 primer Substances 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012520 frozen sample Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462005229P | 2014-05-30 | 2014-05-30 | |
| US62/005,229 | 2014-05-30 | ||
| PCT/US2015/033611 WO2015184461A1 (en) | 2014-05-30 | 2015-06-01 | Methods for typing of lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516501A JP2017516501A (ja) | 2017-06-22 |
| JP2017516501A5 true JP2017516501A5 (cg-RX-API-DMAC7.html) | 2018-07-12 |
Family
ID=54699976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515878A Pending JP2017516501A (ja) | 2014-05-30 | 2015-06-01 | 肺がんのタイピング法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10829819B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3149209B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017516501A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107208131A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2950623A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015184461A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018512160A (ja) * | 2015-04-14 | 2018-05-17 | ジーンセントリック セラピューティクス， インコーポレイテッド | 肺がんのタイピングのための方法 |
| CA3024744A1 (en) | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung squamous cell carcinoma |
| EP3458612B1 (en) | 2016-05-17 | 2023-11-15 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung adenocarcinoma |
| WO2020076897A1 (en) * | 2018-10-09 | 2020-04-16 | Genecentric Therapeutics, Inc. | Detecting cancer cell of origin |
| CN112375826B (zh) * | 2020-12-03 | 2021-08-27 | 远见生物科技（上海）有限公司 | 一种鉴别非小细胞肺癌亚型的环状rna组合物标志物及其应用 |
| CN113186287B (zh) * | 2021-05-10 | 2023-03-24 | 深圳康华君泰生物科技有限公司 | 用于非小细胞肺癌分型的生物标志物及其应用 |
| CN115851927A (zh) * | 2022-08-09 | 2023-03-28 | 上海善准医疗科技有限公司 | 肺鳞癌分子分型及生存风险基因群及诊断产品和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP0773227A1 (en) | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| ATE293011T1 (de) | 1991-11-22 | 2005-04-15 | Affymetrix Inc A Delaware Corp | Kombinatorische strategien für die polymersynthese |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6033860A (en) | 1997-10-31 | 2000-03-07 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US20030092009A1 (en) * | 2000-11-16 | 2003-05-15 | Kaia Palm | Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| EP1444361A4 (en) | 2001-09-28 | 2006-12-27 | Whitehead Biomedical Inst | CLASSIFICATION OF PULMONARY CARCINOMAS BY ANALYSIS OF GENE EXPRESSION |
| US7955800B2 (en) * | 2002-06-25 | 2011-06-07 | Advpharma Inc. | Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US8450057B2 (en) * | 2006-08-14 | 2013-05-28 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| WO2008151110A2 (en) * | 2007-06-01 | 2008-12-11 | The University Of North Carolina At Chapel Hill | Molecular diagnosis and typing of lung cancer variants |
| CN101914542B (zh) * | 2009-04-28 | 2013-03-06 | 中国科学院化学研究所 | 用于不同亚型非小细胞肺癌分型的一种核酸适体及其筛选方法 |
| CN103764844A (zh) * | 2011-03-28 | 2014-04-30 | 罗塞塔金诺米克斯有限公司 | 用于肺癌分类的方法 |
| WO2013172926A1 (en) | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| WO2013190090A1 (en) * | 2012-06-21 | 2013-12-27 | Philip Morris Products S.A. | Gene signatures for classifying and grading lung cancer |
| JP2018512160A (ja) | 2015-04-14 | 2018-05-17 | ジーンセントリック セラピューティクス， インコーポレイテッド | 肺がんのタイピングのための方法 |
| EP3458612B1 (en) | 2016-05-17 | 2023-11-15 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung adenocarcinoma |
| CA3024744A1 (en) | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung squamous cell carcinoma |
-
2015
- 2015-06-01 CN CN201580039130.9A patent/CN107208131A/zh active Pending
- 2015-06-01 US US15/314,773 patent/US10829819B2/en active Active
- 2015-06-01 CA CA2950623A patent/CA2950623A1/en not_active Abandoned
- 2015-06-01 EP EP15800445.7A patent/EP3149209B1/en active Active
- 2015-06-01 WO PCT/US2015/033611 patent/WO2015184461A1/en not_active Ceased
- 2015-06-01 JP JP2017515878A patent/JP2017516501A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516501A5 (cg-RX-API-DMAC7.html) | ||
| US9125923B2 (en) | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy | |
| EP2412821B1 (en) | AREG as a gene expression marker for colorectal cancer prognosis | |
| JP2018512160A5 (cg-RX-API-DMAC7.html) | ||
| US20130040852A1 (en) | Biomarkers based on a multi-cancer invasion-associated mechanism | |
| JP2014512172A (ja) | 胃腸膵神経内分泌新生物（ｇｅｐ−ｎｅｎ）の予測方法 | |
| Carlsen et al. | Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls | |
| CN105431738B (zh) | 胃癌的预后预测模型的建立方法 | |
| JP2010530746A5 (cg-RX-API-DMAC7.html) | ||
| Maxwell et al. | MicroRNAs in endometrial cancers from black and white patients | |
| WO2015056195A1 (en) | Use of microrna markers for diagnosis of liver lesions | |
| KR102096498B1 (ko) | 대장암 진단 또는 재발 예측을 위한 마이크로RNA-4732-5p 및 이의 용도 | |
| CN110229899B (zh) | 用于结直肠癌早期诊断或预后预测的血浆标记物组合 | |
| US20160376661A1 (en) | A method for predicting responsiveness to a treatment with an egfr inhibitor | |
| CA3110668C (en) | Micro-rna signatures for the prediction of liver dysfunction | |
| JP2010523134A (ja) | Ｅｇｆｒ／ｃｓｆ−１／ｃａｉｘ発現に基づき非小細胞肺癌の化学療法計画および生存余命を決定する方法 | |
| Hamdi et al. | Circulating cell-free miRNA expression and its association with clinicopathologic features in inflammatory and non-inflammatory breast cancer | |
| JP2024170603A (ja) | 免疫チェックポイント阻害療法からの利益を予測する方法 | |
| JP2016189746A (ja) | プライマー対、プローブ、薬剤耐性ｃ型肝炎ウイルスの検出キット、薬剤耐性ｃ型肝炎ウイルスの検出方法およびｃ型肝炎の予後予測方法 | |
| KR20200084435A (ko) | 신장이식 환자의 급성거부반응 진단용 miRNA 바이오 마커 및 이의 용도 | |
| JP6442169B2 (ja) | Ｃｄ８＋ｔ細胞の活性化状態の判定方法、ｃｄ４＋ｔ細胞数の増加予測方法、及びｃｄ４＋ｔ細胞数の減少予測方法、並びにそれらのためのキット | |
| WO2017060988A1 (ja) | 免疫状態の判定方法、ｃｄ４＋ｔ細胞数の増加予測方法、及びｃｄ４＋ｔ細胞数の減少予測方法、並びにそれらのためのキット | |
| HK40044800A (en) | Micro-rna signatures for the prediction of liver dysfunction | |
| HK1166350A (en) | Gene expression markers for colorectal cancer prognosis | |
| HK1166111A (en) | Gene expression markers for colorectal cancer prognosis |